For the year ending 2025-12-31, ANIK had $322K increase in cash & cash equivalents over the period. $4,362K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,880 |
| Depreciation | 5,372 |
| Amortization of acquisition related intangible assets | 357 |
| Non-cash operating lease cost | 2,061 |
| (gain) loss on sale of assets | 166 |
| Loss on impairment of long-lived assets | 0 |
| Stock-based compensation expense | 10,084 |
| Deferred income taxes | -7 |
| Provision for doubtful accounts | 265 |
| Provision for inventory | 5,821 |
| Interest income on notes receivable | 896 |
| Accounts receivable | -408 |
| Inventories | -30 |
| Prepaid expenses, other current and long-term assets | -2,327 |
| Accounts payable | 42 |
| Operating lease liabilities | -1,996 |
| Accrued expenses, other current and long-term liabilities | -1,500 |
| Income taxes | -134 |
| Net cash provided by (used in) operating activities | 11,188 |
| Purchases of property and equipment | 6,826 |
| Proceeds from sale of parcus | 4,496 |
| Notes receivable | 1,329 |
| Proceeds from sale of intangible assets | 600 |
| Acquisition of intangible asset | 0 |
| Net cash used in investing activities | -401 |
| Repurchases of common stock | 9,485 |
| Proceeds from employee stock purchase program | 500 |
| Cash paid for tax withheld on vested restricted stock awards | 1,566 |
| Proceeds from exercises of equity awards | 0 |
| Net cash used in financing activities | -10,551 |
| Exchange rate impact on cash | 86 |
| Decrease in cash and cash equivalents | 322 |
| Cash and cash equivalents at beginning of period | 57,159 |
| Cash and cash equivalents at end of period | 57,481 |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)